全球兽医与人类药品市场：2025-2030 年预测

兽用人类药品市场预计将从 2025 年的 37.04 亿美元成长到 2030 年的 42.4 亿美元，复合年增长率为 2.74%。

预计 2025 年至 2030 年，兽用人药市场将经历强劲增长，这主要得益于动物慢性病患病率上升、宠物拥有量增加以及将动物用药品的趋势日益增长。由于对动物有类似的作用且动物用药品产量有限，因此镇痛药（Gabapentin、Pregabalin、Fentanyl）和抗生素等人类动物用药品被用作兽药。仿单标示外增长的伴侣动物数量、诊断技术的进步以及支持性法律规范推动市场的发展。北美引领市场，而亚太地区则展现出强劲的成长潜力。挑战包括抗生素抗药性和监管复杂性。

市场驱动因素

宠物拥有量增加和慢性疾病

宠物饲养数量的成长趋势是推动动物用药品，仿单标示外这些药物在动物身上已被证实有效。由于人口老化和环境压力等因素，伴侣动物和牲畜的慢性疾病盛行率不断上升，这进一步推动了兽用人用药物的需求。

诊断技术的进步

分子技术和快速就地检验等诊断方法的改进，正在提高准确识别动物细菌感染和其他疾病的能力。这些进步使得标靶治疗（尤其是抗生素治疗）成为可能，确保了治疗效果，并推动了对青霉素等已核准用于兽用的人用药物的需求。准确诊断和治疗疾病的能力促进了兽药领域对人用药物日益增长的依赖，从而促进了市场扩张。

支持性法规结构

有利的法规，例如允许使用人用药物治疗常见动物疾病的美国联邦法律，正在推动市场成长。这些法规承认人类与动物之间的基因相似性，并允许使用人类药物（例如止痛药和化疗药物）来治疗动物的癌症和糖尿病等疾病。支持性政策和兽医研究资金的增加进一步促进了人用药物的普及，从而推动了市场成长。

市场限制

健康动物过度使用抗生素加剧了抗生素抗药性的威胁，损害了治疗效果和动物福利。兽药中人用药物的仿单标示外使用有许多监管复杂性，包括安全性和剂量问题，这些都阻碍了抗生素的广泛应用。此外，先进诊断和治疗手段的高昂成本也限制了开发中地区的医疗服务可近性。透过负责任地使用抗生素和简化监管来应对这些挑战，对于永续发展至关重要。

目录

第一章执行摘要

第二章市场概述

• 市场概览
• 市场定义
• 调查范围
• 市场区隔

第三章 经营状况

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策法规
• 策略建议

第四章 技术展望

5. 全球兽药和人药市场（依药物类型）

• 介绍
• 抗生素
• 非类固醇消炎剂
• 阿片类止痛药
• 化疗药物
• 其他的

6. 全球兽药和人药市场（依药物类型）

• 介绍
• 青霉素
• 泼尼松/泼尼松龙
• Diazepam
• 百忧解
• 其他的

7. 全球兽药及人用药市场（依动物型态）

• 介绍
• 伴侣动物
  • 猫
  • 狗
• 家畜
  • 牛
  • 猪
  • 家禽
  • 其他的

8. 全球兽药和人药市场（依给药途径）

• 介绍
• 口服
• 肠外
• 话题

9. 全球兽药及人用药市场（按地区）

• 介绍
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 英国
  • 德国
  • 法国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 以色列
  • 其他的
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 台湾
  • 泰国
  • 印尼
  • 其他的

第十章竞争格局及分析

• 主要企业和策略分析
• 市场占有率分析
• 合併、收购、协议和合作
• 竞争对手仪表板

第十一章：公司简介

• Merck & Co
• Zoetis
• Boehringer Ingelheim
• Elanco Animal Health
• Soparfin SCA
• Ceva Sante Animale
• Virbac SA

第十二章调查方法

The human drugs for veterinary use market is expected to grow from USD 3.704 billion in 2025 to USD 4.240 billion in 2030, at a CAGR of 2.74%.

The global human drugs for veterinary use market is projected to experience robust growth from 2025 to 2030, driven by the rising prevalence of chronic diseases in animals, increasing pet ownership, and the growing trend of using human medications for veterinary purposes. Human drugs, such as painkillers (gabapentin, pregabalin, fentanyl) and antibiotics, are used off-label in veterinary medicine due to their similar effects in animals and the limited production of animal-specific drugs. The market is propelled by the rise in companion animal populations, advancements in diagnostic techniques, and supportive regulatory frameworks. North America leads the market, while Asia-Pacific shows strong growth potential. Challenges include antibiotic resistance and regulatory complexities.

Market Drivers

Rising Pet Ownership and Chronic Diseases

The growing trend of pet ownership is a primary driver, increasing demand for veterinary medicines to manage chronic conditions like heartworm, diabetes, and cancer in companion animals. The rise in pet populations, particularly in developed regions, fuels the need for effective treatments, often met by off-label use of human drugs due to their proven efficacy in animals. The increasing prevalence of chronic diseases in both companion and production animals, driven by factors like aging populations and environmental stressors, further boosts demand for human drugs in veterinary applications.

Advancements in Diagnostic Techniques

Improved diagnostic methods, such as molecular techniques and rapid point-of-care tests, enhance the ability to accurately identify bacterial infections and other conditions in animals. These advancements enable targeted therapies, particularly with antibiotics, ensuring effective treatment and driving demand for human drugs like penicillin, which has been approved for veterinary use. The ability to diagnose and treat conditions with precision supports the growing reliance on human medications in veterinary care, contributing to market expansion.

Supportive Regulatory Frameworks

Favorable regulations, such as U.S. federal laws permitting the use of human medicines for common illnesses in animals, are driving market growth. These regulations recognize the genetic similarities between humans and animals, enabling the use of human drugs like painkillers and chemotherapeutics to treat conditions such as cancer and diabetes in animals. Supportive policies and increased funding for veterinary research further facilitate the adoption of human drugs, boosting market growth.

Market Restraints

The market faces challenges due to the growing threat of antibiotic resistance, driven by the overuse of antibiotics in healthy animals, which compromises treatment efficacy and animal welfare. Regulatory complexities surrounding off-label use of human drugs in veterinary medicine, including safety and dosing concerns, pose barriers to widespread adoption. Additionally, the high cost of advanced diagnostics and treatments may limit access in developing regions. Addressing these challenges through responsible antibiotic use and streamlined regulations will be critical for sustained growth.

Market Segmentation

By Medication Type

The market is segmented into antibiotics, non-steroidal anti-inflammatories, opioid pain relievers, chemotherapeutics, and others. Antibiotics hold a significant share due to the high incidence of bacterial infections in livestock and companion animals, driven by overcrowding and poor hygiene in production facilities. Opioid pain relievers, like fentanyl and buprenorphine, are widely used for pain management in veterinary care.

By End-User

The market includes companion animals and production animals. Companion animals dominate due to rising pet ownership and demand for chronic disease management. Production animals, such as poultry and livestock, are a growing segment, driven by the need for antibiotics and parasiticides to ensure health and productivity.

By Geography

The market is segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. North America leads, driven by advanced veterinary facilities, high pet ownership, and supportive regulations. Asia-Pacific is expected to grow rapidly, fueled by increasing pet populations and expanding livestock industries in countries like China and India. Europe, South America, and the Middle East and Africa are emerging markets, supported by growing veterinary care investments.

The human drugs for veterinary use market is set for robust growth from 2025 to 2030, driven by rising pet ownership, advancements in diagnostics, and supportive regulations. Despite challenges like antibiotic resistance and regulatory hurdles, the market's outlook is positive, particularly in North America and Asia-Pacific. Industry players must focus on responsible drug use, innovative diagnostics, and regulatory compliance to capitalize on the growing demand for human drugs in veterinary applications.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2020 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Market Segmentation:

By Medication Type

• Antibiotics
• Non-steroidal anti-inflammatories
• Opioid pain relievers
• Chemotherapeutics
• Others

By Drug Type

• Penicillin
• Prednisone and Prednisolone
• Diazepam
• Prozac
• Others

By Animal Type

• Companion Animals
• Cat
• Dogs
• Livestock Animals
• Cattle
• Swine
• Poultry
• Others

By Route of Administration

• Oral
• Parenteral
• Topical

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Italy
• Others
• Middle East and Africa
• Saudi Arabia
• Israel
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Indonesia
• Thailand
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL HUMAN DRUGS FOR VETERINARY USE MARKET BY MEDICATION TYPE

• 5.1. Introduction
• 5.2. Antibiotics
• 5.3. Non-steroidal anti-inflammatories
• 5.4. Opioid pain relievers
• 5.5. Chemotherapeutics
• 5.6. Others

6. GLOBAL HUMAN DRUGS FOR VETERINARY USE MARKET BY DRUG TYPE

• 6.1. Introduction
• 6.2. Penicillin
• 6.3. Prednisone and Prednisolone
• 6.4. Diazepam
• 6.5. Prozac
• 6.6. Others

7. GLOBAL HUMAN DRUGS FOR VETERINARY USE MARKET BY ANIMAL TYPE

• 7.1. Introduction
• 7.2. Companion Animals
  • 7.2.1. Cat
  • 7.2.2. Dogs
• 7.3. Livestock Animals
  • 7.3.1. Cattle
  • 7.3.2. Swine
  • 7.3.3. Poultry
  • 7.3.4. Others

8. GLOBAL HUMAN DRUGS FOR VETERINARY USE MARKET BY ROUTE OF ADMINISTRATION

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral
• 8.4. Topical

9. GLOBAL HUMAN DRUGS FOR VETERINARY USE MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. USA
  • 9.2.2. Canada
  • 9.2.3. Mexico
• 9.3. South America
  • 9.3.1. Brazil
  • 9.3.2. Argentina
  • 9.3.3. Others
• 9.4. Europe
  • 9.4.1. United Kingdom
  • 9.4.2. Germany
  • 9.4.3. France
  • 9.4.4. Spain
  • 9.4.5. Others
• 9.5. Middle East & Africa
  • 9.5.1. Saudi Arabia
  • 9.5.2. UAE
  • 9.5.3. Israel
  • 9.5.4. Others
• 9.6. Asia Pacific
  • 9.6.1. Japan
  • 9.6.2. China
  • 9.6.3. India
  • 9.6.4. South Korea
  • 9.6.5. Taiwan
  • 9.6.6. Thailand
  • 9.6.7. Indonesia
  • 9.6.8. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. Merck & Co
• 11.2. Zoetis
• 11.3. Boehringer Ingelheim
• 11.4. Elanco Animal Health
• 11.5. Soparfin SCA
• 11.6. Ceva Sante Animale
• 11.7. Virbac S.A

12. RESEARCH METHODOLOGY